There is rapidly escalating interest in drugs that target the glutamatergic neurotransmitter system, especially NMDA receptor modulators. The hope is that they will fill the large unmet need for rapid-acting antidepressant medications with efficacy in treatment-resistant depression.
Importantly for lay and clinician readers alike, the book Monkey Mind: A Memoir of Anxiety reads as humor-laced triumph with many lost battles along the way rather than enduring unrelenting tragedy.
Grief is the psychological, behavioral, social and physical reaction to a loss that is closely tied to a person’s commitment to heal.
Knowledge of how different antidepressants are likely to affect parameters of sleep can provide an important basis for selecting an appropriate antidepressant drug among the roughly 2 dozen marketed options to meet the needs of depressed patients.
Much of the controversy on the relationship between grief and depression following recent bereavement has focused on whether the so-called “bereavement exclusion” in DSM-IV should be eliminated, as some have proposed, in the DSM-5.
The New York Times ran a front-page story regarding numerous controversies surrounding the DSM-5, most notably, the issue of eliminating the so-called bereavement exclusion in diagnosing a major depressive episode. Here, Dr Pies responds to Dr John Grohol, Psychologist and Editor of the Psychcentral Web site.
Some say that study subjects who are not severely depressed may respond better to placebo than subjects who are severely depressed. Is the data thus unreliable?
In this clip from A&E's Hoarders, Dr Suzanne Chabaud counsels a family living in a hoarding household.
Medicare announced in October that it would pay for depression screening in primary care settings that have “staff-assisted depression care supports” in place to ensure accurate diagnosis, effective treatment, and follow-up.
The race to patent bio-tests for schizophrenia and depression: some say this initiative is destined to fail.
The goal of treating the whole patient, ie, integrating the mind-body connection into mental health care inititiatives, is to provide health care professionals with tactics to effectively identify interdependent conditions of the mind and body that impair psychiatric well-being, as well as strategies for successful treatment and management options in the clinical setting to improve patient care, outcomes, and overall wellness.
The articles by Arline Kaplan and Hagop Akiskal, MD, in the November 2011 issue of Psychiatric Times highlight the race to patent bio-tests for schizophrenia and depression.
Mood and cognitive disorders are major public health problems, and care for patients with such conditions is of growing importance as the population ages. Here, geriatric psychiatrist Jeffrey Lyness, MD, of the University of Rochester School of Medicine and Dentistry in New York offers teaching points about the evaluation of depression in older persons.
Researchers have tried lots of different kinds of tests from EEGs to blood-based biomarkers. Now genetic tests are a very popular means of trying to understand different psychiatric disorders.
A recent study concluded that depression is associated with a significantly increased risk of stroke morbidity and mortality.
A meta-analysis of the Omega-3 fatty acid EPA (eicosapentaenoic acid) as therapeutic supplement for major depression followed the above study online September 6 in the Journal of Clinical Psychiatry.
An initiative from the BRIDGE study group has determined that approximately half of patients presenting with a depressive episode are mistakenly diagnosed with unipolar major depression.
What is associated with increased suicidal risk in soldiers? In what group is the incidence of postpartum depression highest? These questions and more in this quiz.
The first week in October. Leaves fall. Kids start school. Temperatures descend. Weather fluctuates. Stigma decreases. Awareness rises-with the help of the 21st anniversary of NAMI's Mental Illness Awareness Week.
A meta-analysis of depression and risk of stroke finds a positive association. How will this information affect your practice?
Cognitive-behavioral therapy, interpersonal psychotherapy, or antidepressants can be effective treatments for major depression-despite their minimal separation from placebo/control therapies in clinical trials. This article argues that their specific efficacy has not been established.
Newly developed blood tests for schizophrenia and for depression designed to augment current diagnostic approaches have attracted increased attention at recent major scientific meetings.
Treatment resistance in bipolar disorder is clinically familiar but lacks a standard definition. Numerous evidence-based treatments exist for all phases of bipolar disorder, and these should be optimized and fully explored.
For women with metastatic or recurrent breast cancer, reductions in depression symptoms over the first year of a randomized controlled trial predicted longer survival times.
The majority of the literature focuses on prenatal and postnatal depression in mothers, and little attention has been given to the incidence of prenatal and postpartum depression in fathers.
